Document is current
Any future updates will be listed below
-
Authors
Lundberg, Arian
Lindström, Linda S.
Li, Jingmei
Harrell, J. Chuck
Darai-Ramqvist, Eva
Sifakis, Emmanouil G.
Foukakis, Theodoros
Perou, Charles M.
Czene, Kamila
Bergh, Jonas
Tobin, Nicholas P. http://orcid.org/0000-0003-2343-9772
-
Funding
Funding for this research was provided by:
Iris, Stig och Gerry Castenbäcks Stiftelsen
BRECT
Swedish Cancer Society
Cancer Society in Stockholm Personalised Cancer Medicine
King Gustaf V Jubilee Foundation
Swedish Breast Cancer Association
Swedish Research Council (521-2014- 2057)
NCI Breast SPORE program (P50-CA58223-09A1, R01- CA195754-01)
Breast Cancer Research Foundation
National Research Foundation Singapore (NRF-NRFF2017-02)
Konung Gustaf V:s Jubileumsfond
- License Information
-
More Information
Article History
Received: 5 December 2018
Accepted: 14 February 2019
First Online: 28 February 2019
Ethics approval and consent to participate
: Cohort 1 (METABRIC), publicly available data.Cohort 2, both gene expression and genotyping studies were approved by the ethics committee at Karolinska Institutet (Stockholm, Sweden).
: Not applicable
: JB receives research funding from Merck, paid to Karolinska Institutet and from Amgen, Roche, Sanofi-Aventis and Bayer and paid to Karolinska University Hospital. CMP is an equity stock holder, and a board of director member, of BioClassifier LLC and University Genomics. CMP is also listed as an inventor on a patent application on the PAM50 molecular assay. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
